Revolutionizing Vitiligo Virtual Conference - November 13, 2022 - Abstracts and Posters
275 - Diverse Approaches to the Diagnosis and Treatment of Pediatric Vitiligo: A Survey of Pediatric Dermatologists
Mark Weingarten, BA, Michelle Schwartz, MD, and Nanette B. Silverberg, MD
289 - Ritlecitinib (PF-06651600), An Oral JAK3/TEC Inhibitor, Stabilizes Active Lesions and Promotes Re-pigmentation of Stable Lesions in Patients with Active Non-segmental Vitiligo: Results from a Phase 2b, Randomized, Placebo-Controlled, Dose-Ranging Study
Yuji Yamaguchi, Elena Peeva, Ronald Shore, George Han, Lori Ann Cox, Anindita Banerjee, Diamant Thaci, Iltefat Hamzavi, Abigail Sloan, Anand K. Ganesan, Khaled Ezzedine
290 - Quality of Life in Children and Adolescents with Vitiligo
Martha Alejandra, Morales-Sánchez, Ana Karla Díaz-Ortega, María Luisa Peralta-Pedrero
291 - Ritlecitinib (PF-06651600), An Oral JAK3/TEC Inhibitor, Shows Efficacy in Patients with Active Non-segmental Vitiligo and Either a Lighter or Darker Fitzpatrick Skin Type: Results from a Phase 2b, Randomized, Dose-ranging Study with an Extension Period
Elena Peeva, Yuji Yamaguchi, Brett King, George Han, Lori Ann Cox, Anindita Banerjee, Mauro Picardo, Jung Min Bae, Abigail Sloan, Rodney Sinclair, Khaled Ezzedine
295 - Effect of Ruxolitinib Cream on Achievement of VASI50 by Body Region: Week 52 Pooled Analysis of the TRuE-V Phase 3 Studies
Thierry Passeron, MD, PhD, John E. Harris, MD, PhD, Amit G. Pandya, MD, Julien Seneschal, MD, PhD, Pearl Grimes, MD, Deanna Kornacki, PhD, Mingyue Wang, PhD, Kathleen Butler, MD, Khaled Ezzedine, MD, PhD, David Rosmarin, MD
296 - Efficacy and Safety of Ruxolitinib Cream for the Treatment of Vitiligo by Patient Demographics and Baseline Clinical Characteristics: Week 52 Pooled Subgroup Analysis from Two Randomized Phase 3 Studies
Julien Seneschal, MD, PhD, Albert Wolkerstorfer, MD, PhD, Seemal R. Desai, MD, Pearl Grimes, MD, Khaled Ezzedine, MD, PhD, Deanna Kornacki, PhD, Shaoceng Wei, PhD, Kathleen Butler, MD, David Rosmarin, MD
299 - Vitiligo Evidence-Based Expert Consensus Recommendations for Pediatric and Adolescent Patients: Part I - Topical Therapeutics
Yael Renert-Yuval, MD, MSc, Khaled Ezzedine, MD, PhD, Pearl Grimes, MD, David Rosmarin, MD, Lawrence Eichenfield, MD, Leslie Castelo-Soccio MD, PhD, Victor Huang, MD, Seemal R. Desai, MD, Samantha Walsh, MLS, MA, Jonathan I. Silverberg, MD, PhD, MPH, Amy S. Paller, MD, Mark Weingarten, BA, Shanthi Narla, MD, Jackie Gardner, BA, Michael Siegel, PhD, and Nanette B. Silverberg, MD
303 - A Review of the Vitiligo Literature to Standardize Expression of Disease Severity
Nanette Silverberg, MD, Mark Weingarten, BA, Seemal Desai, MD, Victor Huang, MD, Samantha Walsh, MLS, MA, and David Rosmarin, MD
306 - IDEOM Vitiligo Work Group an Update on Our First Year
Nanette B. Silverberg, MD (Co-chair) Arnon Cohen, MD, PhD, MPH, Seemal Desai, MD, Priyanka Francis, Vimala Francis, PhD, Jackie Gardner, Carrie Guarino, Isabella Guarino, Victor Huang, MD, and David Rosmarin, MD (Co-chair) [members are listed in alphabetical order]
307 - Vitiligo is Associated with Mental Health Disorders, Substance Abuse, Cardiovascular Risk Factors and Events, and Venous Thromboembolism: Analysis of the 2015-2019 Nationwide Emergency Department Sample
Jorge A. Rios-Duarte and Jonathan I. Silverberg
- 1
- 2
Results 1 - 10 of 11